recurrent HCV, 2 patients had near-normalization of ALT and bilirubin within 1 year of initiation of therapy. One patient had gradual worsening of jaundice; one patient remained stable. Conclusions: 77% of patients treated for recurrent HCV became intolerant to IFN/ribavirin, stopping therapy after 9 to 330 days. However, treatment rapidly led to improvements in ALT and bilirubin in a majority of patients, including 2 of 4 patients with severe recurrent HCV. A sustained ALT response was achieved in 6 of 13 patients (46%), despite early discontinuation of IFN/ribavirin in one-half of these patients. We support the use of IFN/ribavirin in the treatment of recurrent HCV, in spite of medicationrelated side effects.